Exosome (acellular) therapies
BioSima is a pioneering company that aims to translate exosome therapies from academic research into daily clinical activities in human health, integrating scientific innovations in regenerative medicine with the therapeutic resources already available in medicine, adding a significant improvement in the quality of health and life of people.
We are sure that mechanisms, solutions and possibilities brought about by exosome therapies might generate important impacts on new therapeutic scenarios in Orthopedics and Dentistry, in addition to diagnostic situations and new therapies in several other medical areas.
The growing prevalence of chronic diseases in the population, the increased awareness of exosome technologies and the growing government and private initiatives to increase research funding in the field of regenerative medicine boost the advances in acellular therapies.
In view of these high therapeutic and diagnostic potential, a CAGR growth of 27.89% is projected for the exosome market for the next 5 years, according to Allied Market Research, justifying the significant investments of the public and private sectors verified worldwide.
Meet our
team
Eduardo
Teixeira
Founder e CEO
Patrícia
Sesterheim
Co-founder e CTO
Fernanda
Marques
Research Analyst
Mayara
Mota
Research Analyst
Susinéia
Reis
Administrative Manager
Regina
Barcellos
Research Analyst
Krista
Wartchow
Research Analyst
Parternerships
Investors
Institutional
CNPJ: 47.635.783/0001-43
contato@biosima.bio